Global experience with ixabepilone in breast cancer

References

• Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch. Intern. Med.163(1), 49–56 (2003).
   PubMed Web of Science ®Google Scholar
• Racial/Ethnic Patterns of Cancer in the United States 1988–1992. Miller BA, Kolonel LN, Bernstein L et al. (Eds). National Cancer Institute, Bethesda, MD, USA, NIH publication no. 96–4104 (1996).
   Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype a population-based study from the California Cancer Registry. Cancer109(9), 1721–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Stark A, Kleer CG, Martin I et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer116(21), 4926–4932 (2010).
   PubMed Web of Science ®Google Scholar
• Vallejos CS, Gomez HL, Cruz WR et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a Peruvian hospital database. Clin. Breast Cancer10(4), 294–300 (2010).
   PubMedGoogle Scholar
• Lee R, Mayer K, Dranitsaris G, Verma S. Breast cancer trials: is race an important factor? ASCO Breast Cancer Symposium (2009) (Abstract 139).
   Google Scholar
• Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J. Epidemiol. Community Health58(6), 411–415 (2004).
   PubMedGoogle Scholar
• Ng PC, Zhao Q, Levy S, Strausberg RL, Venter JC. Individual genomes instead of race for personalized medicine. Clin. Pharmacol. Ther.84(3), 306–309 (2008).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G. The implications of population admixture in race-based drug prescription. Clin. Pharmacol. Ther.83(3), 399–400 (2008).
   PubMed Web of Science ®Google Scholar
• Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin. Drug Metab. Toxicol.5(3), 243–257 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez Jimenez P. [Blood and mestizaje in Spanish America]. Anuario Colombiano de Historia Social y de la Cultura35, 279–309 (2008).
   Google Scholar
• Simon SD, Bines J, Barrios CH et al. Clinical characteristics and outcome of treatment of Brazilian women with breast cancer treated at public and private institutions – the AMAZONE project of the Brazilian Breast Cancer Study Group (GBECAM). Cancer Res.69(3 Suppl.), (2009) (Abstract 3082).
   Google Scholar
• Nurena CR. [Incorporation of an intercultural approach in the Peruvian health care system: the vertical birth method]. Rev. Panam. Salud Publica.26(4), 368–376 (2009).
   PubMed Web of Science ®Google Scholar
• Argote L, Toledo GP, Delgado R et al. Factores de riesgo del cancer de mama en pacientes diagnosticadas en el hospital Julio Trigo. Revista Cubana de Salud y Trabajo11(1), 3–6 (2010).
   Google Scholar
• Pazdur R, Douillard JY, Skillings JR et al. Multicenter Phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.18(Suppl.), (1999) (Abstract 1009).
   Google Scholar
• Carmichael J, Popiela T, Radstone S et al. Randomized comparative study of ORZEL (oral uracil/tegafur [UFT] plust leucovorin [LV]) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.18(Suppl.), (1999) (Abstract 1015).
   Google Scholar
• Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J. Clin. Oncol.16(10), 3461–3475 (1998).
   PubMed Web of Science ®Google Scholar
• Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20(17), 3617–3627 (2002).
   PubMed Web of Science ®Google Scholar
• Bourdeanu L, Wong SF. Supporting Asian patients with metastatic breast cancer during ixabepilone therapy. Expert Opin. Drug Saf.9(3), 383–396 (2010).
   PubMed Web of Science ®Google Scholar
• Yip CH. Breast cancer in Asia. Methods Mol. Biol.471, 51–64 (2009).
   PubMedGoogle Scholar
• Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol.24(14), 2158–2163 (2006).
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Toyooka S et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J. Thorac. Oncol.2(7), 632–637 (2007).
   PubMed Web of Science ®Google Scholar
• Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J. Clin. Oncol.26(13), 2118–2123 (2008).
   PubMed Web of Science ®Google Scholar
• Beith JM, Goh BC, Yeo W et al. Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proc. Am. Soc. Clin. Oncol.21(Suppl.), (2002) (Abstract 252).
   Google Scholar
• Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western series. Radiother. Oncol.62(2), 185–189 (2002).
   PubMed Web of Science ®Google Scholar
• Goel S, Cohen M, Comezoglu SN et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin. Cancer Res.14(9), 2701–2709 (2008).
   PubMed Web of Science ®Google Scholar
• Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol.22(10), 2015–2025 (2004).
   PubMed Web of Science ®Google Scholar
• Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res.10(4), 1289–1298 (2004).
   PubMed Web of Science ®Google Scholar
• Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet.45(3), 253–285 (2006).
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Burris HA 3rd, Jones S et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol.25(9), 1082–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Yamamoto N, Yamada Y et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother. Pharmacol.61(5), 751–758 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen M, Mould D, Roy A, Mandava M, Pfister M. A population pharmacokinetic analysis of ixabepilone in patients with cancer. J. Clin. Oncol.26(Suppl. 15), (2008) (Abstract 2521).
   Google Scholar
• Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist13(12), 1207–1223 (2008).
   PubMed Web of Science ®Google Scholar
• Shen H, Lee FY, Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for p-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. DOI: 10.1124/jpet.110.175604 (2011) (Epub ahead of print).
   Google Scholar
• Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol.25(33), 5210–5217 (2007).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Vrdoljak E, Rixe O et al. Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol.28(20), 3256–3263 (2010).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Gomez HL, Li RK et al. Analysis of overall survival from a Phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res. Treat.122(2), 409–418 (2010).
   PubMed Web of Science ®Google Scholar
• Pivot XB, Li RK, Thomas ES et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur. J. Cancer45(17), 2940–2946 (2009).
   PubMedGoogle Scholar
• Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res. Treat.121(2), 261–271 (2010).
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol.25(23), 3407–3414 (2007).
   PubMed Web of Science ®Google Scholar
• Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol.25(23), 3421–3427 (2007).
   PubMed Web of Science ®Google Scholar
• Roche H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol.25(23), 3415–3420 (2007).
   PubMed Web of Science ®Google Scholar
• Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol.23(12), 2726–2734 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol.25(23), 3399–3406 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol.27(4), 526–534 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol.15, 2483–2493 (1997).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology.11(Suppl. 8), 15–18 (1997).
   PubMedGoogle Scholar
• Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J. Clin. Oncol.17, 3412–3417 (1999).
   PubMed Web of Science ®Google Scholar
• Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br. J. Cancer88, 1339–1345 (2003).
   PubMed Web of Science ®Google Scholar
• Estevez LG, Cuevas JM, Antón A et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a Phase II, multicenter study. Clin. Cancer Res.9, 686–692 (2003).
   PubMedGoogle Scholar
• Moulder S, Li H, Wang M et al. A Phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res. Treat.119(3), 663–671 (2010).
   PubMed Web of Science ®Google Scholar
• Melemed AS, O’Shaughnessy J, Nag S et al. Phase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unresectable, locally recurrent, or metastatic breast cancer. Proceedings of: ASCO Breast Cancer Symposium. San Francisco, CA, USA, 7–8 September 2007 (Abstract 150).
   Google Scholar
• O’Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol.20, 2812–2823 (2002).
   PubMed Web of Science ®Google Scholar
• Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J. Clin. Oncol.26(Suppl.), (2008) (Abstract LBA1011).
   Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355, 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Zielinski C, Maarteense E et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP Phase III study (GBG 26/BIG 3–05). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 1025).
   PubMedGoogle Scholar
• Rugo HS, Campone M, Amadori D et al. Randomized Phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J. Clin. Oncol.28(15 Suppl.), (2010) (Abstract 1040).
   Google Scholar
• Watanabe J, Horiguchi J, Masuda N, et al. Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol.28(15 Suppl.), (2010) (Abstract e13095).
   Google Scholar
• Wang J, Fan Y, Xu B. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother. Pharmacol.66(3), 597–603 (2010).
   PubMedGoogle Scholar
• Fein L, Crocamo Ventilari Da Costa S, Gomez H et al. Analysis of Latin American cohort of two large Phase III studies of ixabepilone plus capecitabine in patients with metastatic breast cancer. Presented at: ASCO Breast Cancer Symposium. San Francisco, CA, USA, 8 October 2009 (Abstract 193).
   Google Scholar
• Perez E, Pivot X, Vrdoljak E et al. A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res.69(Suppl. 2), (2008) (Abstract 6140).
   Google Scholar
• Valero V, Bosserman LD, Yardley DA et al. Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): a retrospective analysis of pooled data from two Phase III clinical studies (046/048). J. Clin. Oncol.28(Suppl. 14), (2010) (Abstract 1051).
   Google Scholar